High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.
AstraZeneca PLC (NYSE:AZN)’s breast cancer pill Etcamah (camizestrant) failed to meet the primary endpoint in the Phase III SERENA-4 trial, dealing a setback to one of the company’s key oncology growth opportunities. The trial evaluated Etcamah plus Pfizer’s Ibrance (palbociclib) in previously untreated patients with ER-positive, HER2-negative advanced breast cancer and found a numerical improvement […]
The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.
Collecting $8,900 a month in retirement without selling shares sounds clean until you see what the biggest position in this seven-ticker setup actually pays when markets go quiet.
PFE has underperformed the broader market over the past year, while analysts remain moderately optimistic about its future prospects.
BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical
BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's melanoma triumph, and the fallout is forcing investors to rethink how far mRNA technology can actually reach into solid tumors.
Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell on Friday. Shares of Alnylam (NASDAQ: ALNY) fell nearly 4.9% in pre-market trading following the full presentation of data from a rival drug trial at the European Society of Cardiology Congress in Munich. The detailed results from AstraZeneca and Ionis Pharmaceu
Millions of dollars are available to eligible Chantix buyers, but consumers have until September 14 to submit a claim.
PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts offset weaker COVID demand.
Fuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.
Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost.
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.
Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new international cases that raise legal and operational questions for the company’s COVID-19 vaccine business. See our latest analysis for Pfizer. The legal headlines around Pfizer’s mRNA vaccine coincide with a mixed price pattern, with the stock showing a 1-day share price return of 0.77% and a 7-day share price return of 2.85%, but a...
In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.
Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond the existing U.S. litigation into several international jurisdictions. The lawsuits seek monetary damages and potential injunctions on vaccine products, raising legal and operational risks for Pfizer. Pfizer, listed as NYSE:PFE, is facing an expanded legal challenge as Arbutus Biopharma and Genevant Sciences...
July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch of its newly approved breast cancer drug and treatment-tolerability concerns overshadowed the company's first U. Food and Drug Administration on Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.
The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.
Several Midtown blocks were shut down earlier this week after structural problems put the high-rise building at risk of partial collapse.
AstraZeneca’s shares fell as much as 10.6% in London, which is its largest intraday plummet since 2017, per Bloomberg.
AstraZeneca and Ionis Pharmaceuticals shares are down roughly 8% and 20%, respectively, after the drugmakers said their heart therapy Wainua failed in a late-stage trial. The companies pointed to a smaller group of patients in the trial to show some potential for the drug: Patients who weren’t already taking either Pfizer or BridgeBio’s drug for this condition saw a relative risk reduction in major heart problems or deaths.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...
June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according to letters seen by Reuters.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
